Advanced Enzyme Technologies Limited

rs,

May 13, 2025 BSE Limited P. J. Towers, Dalal Street, Mumbai- 400 001 National Stock Exchange of India Limited Exchange Plaza, Plot No.

02%

idated) Y-o-Y Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 6,239 6,369 2,045 1,944 1,370 1,340 02% 05% 02% FY24 FY25 FY24 FY25 FY24 FY25 Revenue grew by 2 % on y-o-y basis to ₹ 6,369 milli

05%

d) Y-o-Y Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 6,239 6,369 2,045 1,944 1,370 1,340 02% 05% 02% FY24 FY25 FY24 FY25 FY24 FY25 Revenue grew by 2 % on y-o-y basis to ₹ 6,369 million in

2 %

369 2,045 1,944 1,370 1,340 02% 05% 02% FY24 FY25 FY24 FY25 FY24 FY25 Revenue grew by 2 % on y-o-y basis to ₹ 6,369 million in FY25 from ₹ 6,239 million in FY24 EBITDA declined by 5% at

₹ 6,369 million

0 1,340 02% 05% 02% FY24 FY25 FY24 FY25 FY24 FY25 Revenue grew by 2 % on y-o-y basis to ₹ 6,369 million in FY25 from ₹ 6,239 million in FY24 EBITDA declined by 5% at ₹ 1,944 million in FY25 as against

₹ 6,239 million

FY25 FY24 FY25 FY24 FY25 Revenue grew by 2 % on y-o-y basis to ₹ 6,369 million in FY25 from ₹ 6,239 million in FY24 EBITDA declined by 5% at ₹ 1,944 million in FY25 as against ₹ 2,045 million in FY24 on

5%

by 2 % on y-o-y basis to ₹ 6,369 million in FY25 from ₹ 6,239 million in FY24 EBITDA declined by 5% at ₹ 1,944 million in FY25 as against ₹ 2,045 million in FY24 on y-o-y basis PAT de-grew by 5% a

₹ 1,944 million

on y-o-y basis to ₹ 6,369 million in FY25 from ₹ 6,239 million in FY24 EBITDA declined by 5% at ₹ 1,944 million in FY25 as against ₹ 2,045 million in FY24 on y-o-y basis PAT de-grew by 5% at ₹ 1,340 million i

₹ 2,045 million

in FY25 from ₹ 6,239 million in FY24 EBITDA declined by 5% at ₹ 1,944 million in FY25 as against ₹ 2,045 million in FY24 on y-o-y basis PAT de-grew by 5% at ₹ 1,340 million in FY25 as against ₹ 1,370 million i

₹ 1,340 million

t ₹ 1,944 million in FY25 as against ₹ 2,045 million in FY24 on y-o-y basis PAT de-grew by 5% at ₹ 1,340 million in FY25 as against ₹ 1,370 million in FY24 on y-o-y basis EBITDA margin and PAT margin during

₹ 1,370 million

t ₹ 2,045 million in FY24 on y-o-y basis PAT de-grew by 5% at ₹ 1,340 million in FY25 as against ₹ 1,370 million in FY24 on y-o-y basis EBITDA margin and PAT margin during FY25 stands at 31% and 21% respectiv

31%

ainst ₹ 1,370 million in FY24 on y-o-y basis EBITDA margin and PAT margin during FY25 stands at 31% and 21% respectively Notes: On Consolidated Basis PAT is before minority Ind AS adjustments are ca

“Ind AS adjustments are carried out on account of commission, discount, and provision for sales return Earnings Presentation | May 2025 6 Human Nutrition 994 877 1,059 1,107 1,024 1,012 992 1,018 1,031 (₹ in Million) Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 62% of Sales Q4 FY25 Q4 FY24 1,031 1,024 +01% FY25 FY24 (₹ in Million) 64% of Sales 4,053 4,185 -03%”

“• The human nutrition segment contributed around 62% during the quarter to the total revenue from operations • This segment grew by 1% during the quarter from ₹ 1,024 million in Q4 FY24 to ₹ 1,031 million in Q4 FY25 and it also grew by 1% on sequential basis”

“• The human nutrition segment contributed around 64% during the year in the total revenue from operations • This segment de-grew by 3% during the year from ₹ 4,185 million in FY24 to ₹ 4,035 million in FY25”

“All the decimals are rounded off to their relevant nearest number Earnings Presentation | May 2025 7 Animal Nutrition 206 158 173 162 185 172 181 (₹ in Million) 209 197 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 12% of Sales Q4 FY25 Q4 FY24 209 185 +13% FY25 FY24 (₹ in Million) 12% of Sales 760 677 +12%”

“• The animal nutrition segment contributed around 12% during the quarter to the total revenue from operations • This segment grew by 13% during the quarter from ₹ 185 million in Q4 FY24 to ₹ 209 million in Q4 FY25 whereas it grew by 6% on sequential basis”

“• The animal nutrition segment contributed around 12% during the year in the total revenue from operations • This segment grew by 12% on y-o-y basis to ₹ 760 million in FY25 as against ₹ 677 million in FY24”

“224 243 236 258 251 192 168 321 278 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 17% of Sales Q4 FY25 Q4 FY24 278 258 +08% FY25 FY24 (₹ in Million) 16% of Sales 1,018 962 +06%”

“• The Industrial Bio Processing segment contributed about 16% during the year in the total revenue from operations • This segment grew by 6% on y-o-y basis to ₹ 1,018 million • in FY25 from ₹ 962 million in FY24 In this segment, food business contributed 13% to the overall revenue and stood at ₹ 810 million while the Non Food business contributed 3% and stood at ₹ 208 million during the year.”

“The food business grew by 4% while the Non-food business registered a growth of 12% on y-o-y basis Q4 FY25: ₹ 48 mn.”

“Food 14% 9 9 Specialized Manufacturing 113 97 103 104 111 110 120 (₹ in Million) 154 154 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 09% of Sales Q4 FY25 Q4 FY24 154 111 +39% FY25 FY24 (₹ in Million) 08% of Sales 539 415 +30%”

Notes

11

Commentary

8

Contact

1

Notes

On Consolidated Basis PAT is before minority Ind AS adjustments are carried out on account of commission, discount., and provision for sales return Earnings Presentation | May 2025 4 Results Summary – Q4 FY25 (Consolidated) Y-o-Y Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,672 554 1,578 06% 456 18% 299 11% 267 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Q4 FY24 Q4 FY25 Revenue grew by 6% on y-o-y basis to ₹ 1,672 million in Q4 FY25 from ₹ 1,578 million in Q4 FY24 EBITDA de-grew by 18% to ₹ 456 million in Q4 FY25 as against ₹ 554 million in Q4 FY24 on y-o-y basis PAT decreased to ₹ 267 million in Q4 FY25 from ₹ 299 million in Q4 FY24, decline of 11% on y-o-y basis EBITDA margin and PAT margin during Q4 FY25 stands at 27% and 16% respectively

Notes

1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount, and provision for sales return Earnings Presentation | May 2025 5 Results Summary – Q4 FY25 (Consolidated) Q-o-Q Revenue (₹ mn) EBITDA (₹ mn) PAT (₹ mn) 1,691 1,672 553 389 01% 17% 456 31% 267 Q3 FY25 Q4 FY25 Q3 FY25 Q4 FY25 Q3 FY25 Q4 FY25 Revenue declined by 1% on q-o-q basis to ₹ 1,672 million in Q4 FY25 from ₹ 1,691 million in Q3 FY25 EBITDA de-grew by 17% to ₹ 456 million in Q4 FY25 as against ₹ 553 million in Q4 FY25 on sequential basis PAT decreased to ₹ 267 million in Q4 FY25 from ₹ 389 million in Q3 FY25, de-growth of 31% on q-o-q basis

Notes

1. On Consolidated Basis 2. PAT is before minority 3. Ind AS adjustments are carried out on account of commission, discount, and provision for sales return Earnings Presentation | May 2025 6 Human Nutrition 994 877 1,059 1,107 1,024 1,012 992 1,018 1,031 (₹ in Million) Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 62% of Sales Q4 FY25 Q4 FY24 1,031 1,024 +01% FY25 FY24 (₹ in Million) 64% of Sales 4,053 4,185 -03%

Commentary

• The human nutrition segment contributed around 62% during the quarter to the total revenue from operations • This segment grew by 1% during the quarter from ₹ 1,024 million in Q4 FY24 to ₹ 1,031 million in Q4 FY25 and it also grew by 1% on sequential basis

Commentary

• The human nutrition segment contributed around 64% during the year in the total revenue from operations • This segment de-grew by 3% during the year from ₹ 4,185 million in FY24 to ₹ 4,035 million in FY25

Notes

All the decimals are rounded off to their relevant nearest number Earnings Presentation | May 2025 7 Animal Nutrition 206 158 173 162 185 172 181 (₹ in Million) 209 197 Q4 FY23 Q1 FY24 Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 12% of Sales Q4 FY25 Q4 FY24 209 185 +13% FY25 FY24 (₹ in Million) 12% of Sales 760 677 +12%